The Journal of Immunology, Vol 137, Issue 4 1336-1341, Copyright © 1986 by American Association of Immunologists

ARTICLES

Trypanosoma cruzi: characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes

J Scharfstein, M Schechter, M Senna, JM Peralta, L Mendonca-Previato and MA Miles

We have recently described the application of a purified glycoprotein of 25,000 Mr (GP25) of Trypanosoma cruzi in serodiagnosis of Chagas' disease. Purified GP25 lacks appreciable immunogenicity in some animal species, in spite of being generally antigenic to parasitized hosts. The underlying cause for these contrasting observations has not been determined, but it may relate to the drastic extraction conditions used in the original isolation procedure, and possible damage inflicted to the native form of this antigen. This report describes the molecular properties of a GP25-related primary antigen, and a fast performance liquid chromatographic (FPLC) procedure to attain its isolation under gentle conditions. The expression of GP25-related antigen by epimastigotes or bloodstream forms was investigated with a high- affinity monoclonal antibody to GP25, SC11G10, as well as with monospecific antisera to GP25. Immunochemical analysis of Nonidet P-40 lysates supplemented with protease inhibitors indicated that GP25 is not synthesized as such; instead, a 57,000 Mr component (GP57) was identified as the primary antigen product. Partial enzymatic conversion to GP25 was observed when inhibitors were deliberately omitted from cell extracts. Most significantly, GP57 was established as the primary biosynthetic product in [35S]-labeled bloodstream trypomastigotes after immunoprecipitation with SC11G10 antibody. This analysis when applied to metabolically labeled epimastigotes has consistently revealed a minor antigen component of 51,000 Mr (GP51), in addition to GP57. The former was identified as the antigenically related product exposed at the parasite cell surface after external radioiodination of viable trypanosomes. Access to the native form of this widely distributed surface glycoprotein should stimulate the investigation of functional and structural aspects of its immunologic activity.

This article has been cited by other articles:

				D. M. Acosta, M. R. Arnaiz, M. I. Esteva, M. Barboza, D. Stivale, U. D. Orlando, S. Torres, S. A. Laucella, A. S. Couto, and V. G. Duschak Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized mice Int. Immunol., April 1, 2008; 20(4): 461 - 470. [Abstract] [Full Text] [PDF]

				S. Aguirre, A. M. Silber, M. E. F. Brito, M. E. Ribone, C. M. Lagier, and I. S. Marcipar Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection. J. Clin. Microbiol., October 1, 2006; 44(10): 3768 - 3774. [Abstract] [Full Text] [PDF]

				I. S. Marcipar, C. Roodveldt, G. Corradi, M. L. Cabeza, M. E. F. Brito, L. M. F. Winter, A. J. Marcipar, and A. M. Silber Use of Full-Length Recombinant Calflagin and Its C Fragment for Improvement of Diagnosis of Trypanosoma cruzi Infection J. Clin. Microbiol., November 1, 2005; 43(11): 5498 - 5503. [Abstract] [Full Text] [PDF]

				A. R. Schnapp, C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice Infect. Immun., September 1, 2002; 70(9): 5065 - 5074. [Abstract] [Full Text] [PDF]

				A. C. S. Monteiro, M. Abrahamson, A. P. C. A. Lima, M. A. Vannier-Santos, and J. Scharfstein Identification, characterization and localization of chagasin, a tight-binding cysteine protease inhibitor in Trypanosoma cruzi J. Cell Sci., January 11, 2001; 114(21): 3933 - 3942. [Abstract] [Full Text] [PDF]

				G. Lalmanach, F. Lecaille, J. R. Chagas, E. Authie, J. Scharfstein, M. A. Juliano, and F. Gauthier Inhibition of Trypanosomal Cysteine Proteinases by Their Propeptides J. Biol. Chem., September 25, 1998; 273(39): 25112 - 25116. [Abstract] [Full Text] [PDF]

				Y. Zhang, X. Guo, E. T. Lin, and L. Z. Benet Overlapping Substrate Specificities of Cytochrome P450 3A and P-Glycoprotein for a Novel Cysteine Protease Inhibitor Drug Metab. Dispos., April 1, 1998; 26(4): 360 - 366. [Abstract] [Full Text]

				J. Engel, P. Doyle, J Palmer, I Hsieh, D. Bainton, and J. McKerrow Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi J. Cell Sci., January 3, 1998; 111(5): 597 - 606. [Abstract] [PDF]

				E. Del Nery, M. A. Juliano, A. P. C. A. Lima, J. Scharfstein, and L. Juliano Kininogenase Activity by the Major Cysteinyl Proteinase (Cruzipain) from Trypanosoma cruzi J. Biol. Chem., October 10, 1997; 272(41): 25713 - 25718. [Abstract] [Full Text] [PDF]

				L. Verdot, G. Lalmanach, V. Vercruysse, S. Hartmann, R. Lucius, J. Hoebeke, F. Gauthier, and B. Vray Cystatins Up-regulate Nitric Oxide Release from Interferon-gamma - activated Mouse Peritoneal Macrophages J. Biol. Chem., November 8, 1996; 271(45): 28077 - 28081. [Abstract] [Full Text] [PDF]